Innate Pharma reports Phase II clinical data with IPH 1101 in oncology

• Encouraging interim efficacy data in non-Hodgkin’s lymphoma (“NHL”) reported at the ESMO meeting in Berlin; complete response rate above current standard of care for the first set of patients
• Enrolment of patients in the initial Phase I/II and Phase IIa program with IPH 1101 started in 2006 completed; final data to open window for partnering discussions

Conference call held September 21, 2009 :
during which Pr. Laurent, co-lead investigator of the NHL trial, has presented the interim results.

The slideshow is available here: